Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

doi:10.1158/1078-0432.CCR-06-0773

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2006

Wen Patrick Y, Yung W K Alfred, Lamborn Kathleen R, Dahia Patricia L, Wang Yanfeng, Peng Bin, Abrey Lauren E, Raizer Jeffrey, Cloughesy Timothy F, Fink Karen, Gilbert Mark, Chang Susan, Junck Larry, Schiff David, Lieberman Frank, Fine Howard A, Mehta Minesh, Robins H Ian, DeAngelis Lisa M, Groves Morris D, Puduvalli Vinay K, Levin Victor, Conrad Charles, Maher Elizabeth A, Aldape Kenneth, Hayes Michael, Letvak Laurie, Egorin Merrill J, Capdeville Renaud, Kaplan Richard, Murgo Anthony J, Stiles Charles, Prados Michael D

Abstract excerpt

PURPOSE: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not taking EIAED. Phase II: To determine the therapeutic efficacy of imatinib. EXPERIMENTAL DESIGN: Phase I component used an interpatient dose escalation scheme. End points of the phase II component...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Brain Neoplasms

Share to Drug Interactions

Share to Glioma

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 16914578
DOI: 10.1158/1078-0432.CCR-06-0773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.PMID 16914578Read ↗

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.Semantic proximity Read ↗

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Semantic proximity Read ↗

Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokineticsSemantic proximity Read ↗

Characterization of an imatinib-sensitive subset of high-grade human glioma culturesSemantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaSemantic proximity Read ↗

Targeting EGFR in glioblastoma with a novel brain-penetrant small molecule EGFR-TKISemantic proximity Read ↗

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.Semantic proximity Read ↗

Genetic polymorphisms are associated with imatinib plasma levels and periorbital edema in Chinese patients with gastrointestinal stromal tumors receiving adjuvant imatinibSemantic proximity Read ↗

Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.Semantic proximity Read ↗

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.